These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34422119)

  • 1. Immune checkpoint inhibitors in ovarian cancer: where do we stand?
    Leary A; Tan D; Ledermann J
    Ther Adv Med Oncol; 2021; 13():17588359211039899. PubMed ID: 34422119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer.
    Indini A; Nigro O; Lengyel CG; Ghidini M; Petrillo A; Lopez S; Raspagliesi F; Trapani D; Khakoo S; Bogani G
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to synergize PD-1/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer.
    Zhao L; Chen X; Wu H; He Q; Ding L; Yang B
    Biochem Pharmacol; 2023 Sep; 215():115724. PubMed ID: 37524205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    Gupta T; Vinayak S; Telli M
    Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer.
    Meng J; Peng J; Feng J; Maurer J; Li X; Li Y; Yao S; Chu R; Pan X; Li J; Zhang T; Liu L; Zhang Q; Yuan Z; Bu H; Song K; Kong B
    J Transl Med; 2021 Oct; 19(1):415. PubMed ID: 34620163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results.
    Goncalves A; Mezni E; Bertucci F
    Curr Opin Oncol; 2020 Nov; 32(6):585-593. PubMed ID: 32852311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1.
    Chardin L; Leary A
    Front Oncol; 2021; 11():795547. PubMed ID: 34966689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease.
    Arend RC; Jackson-Fisher A; Jacobs IA; Chou J; Monk BJ
    Cancer Biol Ther; 2021 Feb; 22(2):89-105. PubMed ID: 33427569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma.
    Yu WB; Rao JY
    Chronic Dis Transl Med; 2019 Sep; 5(3):170-177. PubMed ID: 31891128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
    Saeed A; Park R; Sun W
    J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
    Rizzo A; Mollica V; Massari F
    Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery.
    Colombo I; Karakasis K; Suku S; Oza AM
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug.
    Shen N; Yang C; Zhang X; Tang Z; Chen X
    Acta Biomater; 2021 Nov; 135():543-555. PubMed ID: 34400305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.
    Revythis A; Limbu A; Mikropoulos C; Ghose A; Sanchez E; Sheriff M; Boussios S
    Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
    Remon J; Chaput N; Planchard D
    Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.